About Us

Precision Proteomics Inc. (PPI) is a biotechnology company commercializing a novel proteomics platform for basic, pre-clinical and clinical research and for the development of next-generation precision medicines. PPI’s patented technology – including the SH2 Supberbinder (SH2S)- enables cutting-edge proteomics to serve the needs of our customers and collaborators in research, development and clinical utilization of therapeutics. PPI’s technology can systematically and quantitatively profile activations of key signal pathways and regulatory networks that drive pathogenesis or the development of resistance to therapy. Besides providing valuable insights to mechanism of action for targeted therapy and immunotherapy, PPI’s technology enables the identification of protein biomarkers for the precise utilization of therapuetics. The company is actively building research and development partnerships with academic institutions biopharmaceutical companies globally. Precision Proteomics Inc. has offices in London, Ottawa, and Toronto, Ontario, Canada.